The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2021 | IMbrave150: updated data on atezo plus bev versus sorafenib in HCC
Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III IMbrave150 trial (NCT03434379) investigating atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). At a median of 15.6 months atezo plus bev reported a greater median overall survival and median progression-free survival versus sor, regardless of risk categorization. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Peter R. Galle, MD, PhD, discloses links to Adaptimmune, Bayer, BMS, AstraZeneca, Sirtex, MSD, Eisai, Ipsen, Roche and Lilly.
